The role of cytotoxic chemotherapy in the management of progressive glioblastoma
What is the impact of cytotoxic chemotherapy on disease control and survival in the adult patient with progressive glioblastoma?
This recommendation applies to adults patients with progressive glioblastoma.
Temozolomide is recommended as superior to procarbazine in patients with first relapse of glioblastoma after having received nitrosourea chemotherapy or no prior cytotoxic chemotherapy at the time of initial therapy.
The use of BCNU-impregnated biodegradable polymer wafers is recommended in the management of progressive glioblastoma as a surgical adjunct when cytoreductive surgery is indicated, taking into account the associated toxicities seen with this modality.
Consideration of a variety of cytotoxic chemotherapy agents of uncertain benefit is recommended in the setting of progressive glioblastoma based on the judgment of the treating physician taking into account the individual patients prior treatment exposure, systemic health, and likelihood of tolerance of the toxicities of any given agent. It is recommended in such cases that enrollment in available clinical trials be encouraged.
KeywordsAdult Chemotherapy Cytotoxic Glioblastoma Mortality Progressive Recurrent Relapsing Survival Temozolomide
We would like to acknowledge the AANS/CNS Joint Guidelines Committee for their review, comments and suggestions, the contributions of Laura Mitchell, CNS Guidelines Manager for organizational assistance, Maxine Brown for searching for and retrieving literature and Amy Allison for reference library consultations. We would also like to acknowledge the following individual JGC members for their contributions throughout the review process: Sepideh Amin-Hanjani, MD, FAANS, FACS, FAHA, Martina Stippler, MD, Alexander Khalessi, MD, Isabelle Germano, MD, Sean D. Christie, MD, FRCS (C), Gregory J. Zipfel, MD, Zachary Litvack, MD, MCR, Ann Marie Flannery, MD, Patricia B Raksin, MD, Joshua M. Rosenow, MD, FACS, Steven Casha, MD, PhD, Julie G. Pilitsis, MD, PhD, Gabriel Zada, MD, Adair Prall, Krystal Tomei, MD, Gregory W Hawryluk, MD.
Conflict of interest
Task Force members report potential COIs prior to beginning work on the guideline and at the time of publication. COI disclosures are reviewed by the Task Force Chair and taken into consideration when determining writing assignments. Resolution of potential COIs included Task Force members were assigned to chapters that did not involve or in any way relate to the potential COIs disclosed.
Disclaimer of liability
The information in these guidelines reflects the current state of knowledge at the time of completion. The presentations are designed to provide an accurate review of the subject matter covered. These guidelines are disseminated with the understanding that the recommendations by the authors and consultants who have collaborated in their development are not meant to replace the individualized care and treatment advice from a patient’s physician(s). If medical advice or assistance is required, the services of a physician should be sought. The proposals contained in these guidelines may not be suitable for use in all circumstances. The choice to implement any particular recommendation contained in these guidelines must be made by a managing physician in light of the situation in each particular patient and on the basis of existing resources.
These guidelines were funded exclusively by the CNS and Tumor Section of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons whom received no funding from outside commercial sources to support the development of this document unless otherwise stated in this section.
- 1.CBTRUS (2010) CBTRUS Statistical Report: Primary brain and central nervous system tumors in the United States in 2004–2006. Published by the Central Brain Tumor Registry of the United States, HinsdaleGoogle Scholar
- 5.Easaw JC, Mason WP, Perry J, et al (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol (Toronto, Ont.) 18(3):e126–e136Google Scholar
- 17.Kong DS, Lee JI, Kim WS, et al (2006) A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16:1117–1121Google Scholar
- 29.Taal W, Segers-van Rijn JM, Kros JM, et al (2012) Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. J Neurooncol 108(1):195–200Google Scholar
- 34.Stupp R, Tosoni A, Bromberg JE, et al (2011) Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol 22(9):2144–2149Google Scholar
- 41.Perry J, Chambers A, Spithoff K, Laperriere N (2007) Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol (Toronto, Ont.). 14(5):189–194Google Scholar
- 42.Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D (1999) Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery.45(1):17–22; discussion 22-13Google Scholar
- 45.Frenay M, Giroux B, Khoury S, Derlon JM, Namer M (1991) Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer (Oxford, England: 1990). 27(7):852–856Google Scholar
- 47.Brandes AA, Tosoni A, Franceschi E et al (2009) Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 64(4):769–775PubMedCentralPubMedCrossRefGoogle Scholar
- 52.Gregor A, Rampling R, Aapro M, et al (1992) Phase II study of tauromustine in malignant glioma. Eur J Cancer (Oxford, England:1990). 28A(12):1959–1962Google Scholar
- 56.Prados MD, Lamborn K, Yung WKA et al (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol 8:189–193Google Scholar
- 57.Bruce JN, Fine RL, Canoll P, et al (2011) Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery. 69(6):1272–1279; discussion 1279-1280Google Scholar
- 60.Murray LJ, Bridgewater CH, Levy D (2011) Carboplatin chemotherapy in patients with recurrent high-grade glioma. Clin Oncol (Royal College of Radiologists Great Britain). 23(1):55–61Google Scholar
- 66.van den Bent MJ, Grisold W, Frappaz D et al (2003) European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-min infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 14(12):1732–1734PubMedCrossRefGoogle Scholar
- 83.Prados MD, Seiferheld W, Sandler HM et al (2004) Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys. 58(4):1147–1152PubMedCrossRefGoogle Scholar
- 87.Brandes AA, Tosoni A, Basso U et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22(23):4779–4786PubMedCrossRefGoogle Scholar
- 94.Sanson M, Ameri A, Monjour A, et al (1996) Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur J Cancer (Oxford, England: 1990). 32A(13):2229–2235Google Scholar
- 108.Demeule M, Regina A, Che C et al (2008) Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exper Ther 324(3):1064–1072Google Scholar
- 111.van den Bent MJ, Pronk L, Sillevis Smitt PAE et al (1999) Phase II study of weekly dose intensified cisplatin chemotherapy with oral etoposide in recurrent glioma. J Neurooncol 44:59–64Google Scholar
- 112.Stein ME, Kuten A, Drumea K et al (1999) Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure: a clinical study conducted at the Northern Israel Oncology Center. J Surg Oncol 71(3):167–170Google Scholar